Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro

Six months of adjuvant nivolumab plus ipilimumab after nephrectomy for renal cell carcinoma offers no disease-free survival benefit, reveals trial that highlights treatment duration and tolerability.
Medscape Medical News

source https://www.medscape.com/viewarticle/980547?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost